Cargando…
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented. We evaluated the efficacy of mitotane treatment of 96 patients with adrenocortical carcino...
Autores principales: | Haak, H. R., Hermans, J., van de Velde, C. J., Lentjes, E. G., Goslings, B. M., Fleuren, G. J., Krans, H. M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968906/ https://www.ncbi.nlm.nih.gov/pubmed/8180029 |
Ejemplares similares
-
Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994) -
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019) -
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021) -
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022) -
Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma.
por: Haak, H. R., et al.
Publicado: (1993)